Selective use of PET scan in the preoperative staging of NSCLC.

[1]  R. Brooks,et al.  PET-FDG of untreated and treated cerebral gliomas. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  A. Wolf,et al.  Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  G. Lillington,et al.  Management of solitary pulmonary nodules. , 1991, Disease-a-month : DM.

[4]  P Schmidlin,et al.  Recurrence of colorectal tumors: PET evaluation. , 1989, Radiology.

[5]  L G Strauss,et al.  The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  R. Coleman,et al.  Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. , 1993, Radiology.

[7]  M E Phelps,et al.  Whole-Body Positron Emission Tomography and Fluorodeoxyglucose , 2006 .

[8]  N. Gupta,et al.  Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose , 1994 .

[9]  Y. Ichinose,et al.  Preoperative examination to detect distant metastasis is not advocated for asymptomatic patients with stages 1 and 2 non-small cell lung cancer. Preoperative examination for lung cancer. , 1989, Chest.

[10]  V J Lowe,et al.  Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). , 1995, The Journal of thoracic and cardiovascular surgery.

[11]  T Jones,et al.  Glucose utilization in vivo by human pulmonary neoplasms , 1987, Cancer.

[12]  E H Moore,et al.  Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. , 1992, Radiology.

[13]  M E Phelps,et al.  Whole-body positron emission tomography: Part I. Methods and performance characteristics. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  J. Shirlaw.  THE METABOLISM OF TUMOURS , 1931 .

[15]  M. Matthews,et al.  Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. , 1973, Cancer chemotherapy reports. Part 3.

[16]  C. Sanders.  Transthoracic needle aspiration. , 1992, Clinics in chest medicine.

[17]  R. Wahl,et al.  18F‐2‐deoxy‐2‐fluoro‐D‐glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron‐emission tomography , 1991, Cancer.

[18]  M. Ito,et al.  Imaging of breast cancer with [18F]fluorodeoxyglucose and positron emission tomography. , 1989, Journal of computer assisted tomography.

[19]  Abass Alavi,et al.  Positron emission tomography in patients with glioma a predictor of prognosis , 1988, Cancer.

[20]  M P Frick,et al.  Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. , 1993, Chest.

[21]  V. Lowe,et al.  Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. , 1994, Radiology.

[22]  J. Sunderland,et al.  Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1992, Radiology.

[23]  J. Hatazawa,et al.  Experimental study for cancer diagnosis with positron-labeled fluorinated glucose analogs: [18F]-2-fluoro-2-deoxy-D-mannose: A new tracer for cancer detection , 1982, European Journal of Nuclear Medicine.

[24]  P. Valk,et al.  Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. , 1995, The Annals of thoracic surgery.

[25]  B J McNeil,et al.  CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. , 1991, Radiology.

[26]  A. M. Salazar,et al.  The role of transthoracic needle biopsy for the diagnosis and staging of lung cancer. , 1993, Clinics in Chest Medicine.